Human natural killer cells: A unique innate immunoregulatory role for the CD56bright subset

Blood

Volumn 97, Issue 10, 2001, Pages 3146-3151

  Cooper, Megan A ^a,b,c,d,e   Fehniger, Todd A ^a,b,c,d,e   Turner, Sarah C ^a,b,c,d,e   Chen, Kenneth S ^a,b,c,d,e   Ghaheri, Bobak A ^a,b,c,d,e   Ghayur, Tariq ^a,b,c,d,e   Carson, William E ^a,b,c,d,e   Caligiuri, Michael A ^a,b,c,d,e,f  

^a Division of Hematology/Oncology   (United States)

^b Division of Human Cancer Genetics   (United States)

^c Department of Surgery ^*  (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e BASF Bioresearch Corporation   (United States)

^f THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 13; LYMPHOTOXIN; MONOKINE;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HOST RESISTANCE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREGULATION; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM;

EID: 0035874522     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.10.3146     Document Type: Article

References (36)

1. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood. 1990;76:2421-2438.
2. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol. 1999;17:189-220.
3. Bancroft GJ. The role of natural killer cells in innate resistance to infection. Curr Opin Immunol. 1993;5:503-510.
4. Scharton-Kersten TM, Sher A. Role of natural killer cells in innate resistance to protozoan infections. Curr Opin Immunol. 1997;9:44-51.
5. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol. 1986;136:4480-4486.
6. Caligiuri MA, Zmuidzinas A, Manley TJ, Levine H, Smith KA, Ritz J. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes: identification of a novel natural killer cell subset with high affinity receptors. J Exp Med. 1990;171:1509-1526.
7. Baume DM, Robertson MJ, Levine H, Manley TJ, Schow PW, Ritz J. Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells. Eur J Immunol. 1992;22:1-6.
8. Caligiuri MA, Murray C, Robertson MJ, et al. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest. 1993;91:123-132.
9. Matos ME, Schnier GS, Beecher MS, Ashman LK, William DE, Caligiuri MA. Expression of a functional c-kit receptor on a subset of natural killer cells. J Exp Med. 1993;178:1079-1084.
10. bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand. Eur J Immunol. 1997;27:354-360.
11. Nagler A, Lanier LL, Cwirla S, Phillips JH. Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol. 1989;143:3183-3191.
12. Ellis TM, Fisher RI. Functional heterogeneity of Leu 19"bright"+ and Leu 19"dim"+ lymphokine-activated killer cells. J Immunol. 1989;142:2949-2954.
13. Robertson MJ, Soiffer RJ, Wolf SF, et al. Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med. 1992;175:779-788.
14. Voss SD, Daley J, Ritz J, Robertson MJ. Participation of the CD94 receptor complex in costimulation of human natural killer cells. J Immunol. 1998;160:1618-1626.
15. Andre P, Spertini O, Guia S, et al. Modification of P-selectin glycoprotein ligand-1 with a natural killer cell-restricted sulfated lactosamine creates an alternate ligand for L-selectin. Proc Natl Acad Sci U S A. 2000;97:3400-3405.
16. dim natural killer cell subsets. J Immunol. 1998;161:400-408.
17. Carson WE, Giri JG, Lindemann MJ, et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med. 1994;180:1395-1403.
18. Fehniger TA, Shah MH, Turner MJ, et al. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol. 1999;162:4511-4520.
19. Aste-Amezaga M, D'Andrea A, Kubin M, Trinchleri G. Cooperation of natural killer cell stimulatory factor/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules in human T and NK cells. Cell Immunol. 1994;156:480-492.
20. Wang KS, Frank DA, Ritz J. Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT-4. Blood. 2000;95:3183-3190.
21. Held CA, Stevens J, Livak KJ, Williams PM. Real-time quantitative PCR. Genome Res. 1996;6:986-994.
22. Carson WE, Ross ME, Baiocchi RA, et al. Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-gamma by natural killer cells in vitro. J Clin Invest. 1995;96:2578-2582.
23. D'Andrea A, Rengaraju M, Valiante NM, et al. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med. 1992;176:1387-1398.
24. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87:2095-2147.
25. Peritt D, Robertson S, Gri G, Showe L, Aste-Amezaga M, Trinchieri G. Differentiation of human NK cells into NK1 and NK2 subsets. J Immunol. 1998;161:5821-5824.
26. Romagnani S. Induction of TH1 and TH2 responses: a key role for the "natural" immune response? Immunol Today. 1992;13:379-381.
27. Morel PA, Oriss TB. Cross-regulation between Th1 and Th2 cells. Crit Rev Immunol. 1998;18:275-303.
28. Long EO. Regulation of immune responses through inhibitory receptors. Annu Rev Immunol. 1999;17:875-904.
29. Leibson PJ. Signal transduction during natural killer cell activation: inside the mind of a killer. Immunity. 1997;6:655-661.
30. + hematopoietic progenitor cells. Blood. 1996;87:2632-2640.
31. Kennedy MK, Glaccum M, Brown SN, et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med. 2000;191:771-780.
32. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood. 2001;97:14-32.
33. Yu H, Fehniger TA, Fuchshuber P, et al. Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15. Blood. 1998;92:3647-3657.
34. Parrish-Novak J, Dillon SR, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature. 2000;408:57-63.
35. Fehniger TA, Bluman EM, Porter MM, et al. Potential mechanisms of human natural killer cell expansion in vivo during/low-dose IL-2 therapy. J Clin Invest. 2000;106:117-124.
36. Shah MH, Baiocchi RA, Fehniger TA, et al. Cytokine replacement in patients with HIV-1 non-Hodgkin's lymphoma: the rationale for low-dose interleukin-2 therapy. Cancer J Sci Am. 2000;6: S45-S51.